Valproic Acid
Valproic acid (and its derivatives divalproex sodium) is an anticonvulsant with mood-stabilizing properties indicated for epilepsy, bipolar disorder, and migraine prevention. It is considered a first-line mood stabilizer for bipolar disorder and is particularly effective for manic episodes, mixed states, and rapid cycling. It has a broad spectrum of activity but requires careful monitoring due to potential serious side effects.
Clinical Overview
Primary Clinical Applications
Valproic acid is indicated for complex partial seizures, absence seizures, manic episodes of bipolar disorder, and migraine prophylaxis. It is particularly effective for rapid cycling bipolar disorder, mixed episodes, and patients with comorbid substance abuse. It may also be used for maintenance therapy in bipolar disorder.
Mechanism and Clinical Benefits
Valproic acid enhances GABA neurotransmission, blocks voltage-gated sodium channels, and affects multiple other neurotransmitter systems. Its mood-stabilizing effects may involve modulation of protein kinase C, gene expression, and neuroprotective mechanisms. The broad mechanism provides efficacy across multiple psychiatric and neurological conditions.
Monitoring Requirements
Valproic acid requires regular monitoring of liver function, complete blood count, and serum levels due to risks of hepatotoxicity, thrombocytopenia, and other serious adverse effects. Therapeutic drug monitoring is essential with target levels of 50-125 mcg/mL for mood disorders. Special attention is needed for teratogenic risks in women of childbearing potential.
Key Clinical Points
Boxed warning covers three separate risks
Hepatotoxicity, teratogenicity, and pancreatitis, each potentially fatal. Liver function requires close monitoring particularly during the first six months.
Highest teratogenic risk of the mood stabilisers
Major congenital malformations and neurodevelopmental effects mean effective contraception is essential in patients of childbearing potential, and alternatives should be considered first.
Doubles lamotrigine concentrations
The single most clinically important interaction in bipolar prescribing. Lamotrigine titration and target dose must be halved when valproate is co-prescribed, or serious rash risk rises.
Target level 50 to 125 mcg/mL for mood
Monitoring should also cover full blood count for thrombocytopenia and ammonia, since hyperammonaemic encephalopathy can occur with normal liver function, especially alongside topiramate.
Contraindicated in POLG mitochondrial disorders
Also contraindicated in hepatic disease and urea cycle disorders. Long-term use is associated with weight gain, hair loss, osteoporosis, and polycystic ovary syndrome.
Prescribing Information
Dosing & Administration
Bipolar Disorder – Manic Episodes:
- Initial: 750 mg daily in divided doses
- Titration: Increase rapidly to achieve therapeutic levels
- Range: 1000-3000 mg daily
- Target level: 50-125 mcg/mL
Epilepsy:
- Initial: 10-15 mg/kg/day
- Maintenance: 30-60 mg/kg/day
- Maximum: 60 mg/kg/day
Migraine Prophylaxis:
- Initial: 250 mg twice daily
- Range: 500-1000 mg daily
- Extended release: 500-1000 mg once daily
Administration:
- Take with food to reduce GI upset
- Divide immediate-release doses 2-3 times daily
- Extended-release: Once daily, swallow whole
- Regular monitoring of serum levels
Indications
- Complex partial seizures
- Simple and complex absence seizures
- Manic episodes associated with bipolar disorder
- Migraine prophylaxis
Contraindications
- Hepatic disease or significant hepatic dysfunction
- Known mitochondrial disorders (POLG mutations)
- Hypersensitivity to valproic acid
- Urea cycle disorders
Warnings & Precautions
- Boxed Warning: Hepatotoxicity (potentially fatal), teratogenicity, pancreatitis
- Hepatotoxicity: Monitor liver function regularly, especially first 6 months
- Teratogenicity: Major birth defects, avoid in pregnancy when possible
- Pancreatitis: Life-threatening, monitor for symptoms
- Thrombocytopenia: Monitor platelet count
- Hyperammonemia: Can cause encephalopathy
- Suicidal thoughts: Monitor for behavioral changes
Drug Interactions
- Lamotrigine: Valproic acid significantly increases lamotrigine levels
- Carbamazepine: Bidirectional interactions, monitor levels
- Phenytoin: Displaces from protein binding, monitor free levels
- Aspirin: Increases valproic acid levels and bleeding risk
- Topiramate: Increased risk of hyperammonemia and encephalopathy
Adverse Reactions
Common (>10%):
- Nausea, vomiting, diarrhea, dizziness, somnolence
- Weight gain, hair loss, tremor
Serious:
- Hepatotoxicity, pancreatitis, thrombocytopenia
- Hyperammonemia, birth defects
Long-term:
- Weight gain, hair loss, osteoporosis, polycystic ovary syndrome
Special Populations
- Women of childbearing age: High teratogenic risk, use effective contraception
- Pregnancy: Category D/X – avoid if possible, high risk of birth defects
- Hepatic Impairment: Contraindicated in hepatic disease
- Elderly: Start with lower doses, monitor for drug interactions
- Monitoring: LFTs, CBC, ammonia, therapeutic drug levels
Frequently Asked Questions
What is Valproic Acid used for?
Valproic acid (and its derivatives divalproex sodium) is an anticonvulsant with mood-stabilizing properties indicated for epilepsy, bipolar disorder, and migraine prevention. It is considered a first-line mood stabilizer for bipolar disorder and is particularly effective for manic episodes, mixed states, and rapid cycling. It has a broad spectrum of activity but requires careful monitoring due to potential serious side effects.
What class of drug is Valproic Acid?
Valproic Acid is classified as: Anticonvulsant/Mood Stabilizer.
Boxed warning covers three separate risks?
Hepatotoxicity, teratogenicity, and pancreatitis, each potentially fatal. Liver function requires close monitoring particularly during the first six months.
Highest teratogenic risk of the mood stabilisers?
Major congenital malformations and neurodevelopmental effects mean effective contraception is essential in patients of childbearing potential, and alternatives should be considered first.
Doubles lamotrigine concentrations?
The single most clinically important interaction in bipolar prescribing. Lamotrigine titration and target dose must be halved when valproate is co-prescribed, or serious rash risk rises.
Target level 50 to 125 mcg/mL for mood?
Monitoring should also cover full blood count for thrombocytopenia and ammonia, since hyperammonaemic encephalopathy can occur with normal liver function, especially alongside topiramate.
Source: FDA prescribing information (DailyMed)